Retatrutide is an investigational peptide designed to activate GIP, GLP-1, and glucagon receptors. It has been studied in clinical development for obesity and metabolic disease.

The Sixpex listing identifies a 10 mg strength, but its exact formulation, dosage form, package size, and manufacturing specifications are not established from the supplied information.

Retatrutide is not an FDA-approved active ingredient in an approved medicine. FDA enforcement materials have also addressed retatrutide products marketed for human use.